MAIA (MAIA) director receives grant of 27,258 stock options

Rhea-AI Filing Summary

MAIA Biotechnology director Ramiro Guerrero received a grant of stock options as equity compensation. He was awarded 27,258 stock options on March 31, 2026 with an exercise price of $1.40 per share, each option representing one share of common stock.

The options were granted under MAIA Biotechnology, Inc.’s 2021 Equity Incentive Plan, vest 100% on the grant date, and are exercisable beginning March 31, 2026. Following this grant, Guerrero holds 27,258 stock options directly, with the options scheduled to expire on March 31, 2036.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Guerrero Ramiro

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options	27,258	$0.00	--

Holdings After Transaction: Stock Options — 27,258 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Stock options granted: 27,258 options Exercise price: $1.40 per share Post-grant option holdings: 27,258 options +2 more

5 metrics

Stock options granted 27,258 options Grant to director Ramiro Guerrero on March 31, 2026

Exercise price $1.40 per share Strike price for Guerrero’s 27,258 stock options

Post-grant option holdings 27,258 options Total stock options held following the reported transaction

Vesting 100% on grant date Options vest fully on March 31, 2026

Expiration date March 31, 2036 Final exercise date for granted stock options

Key Terms

Stock Options, 2021 Equity Incentive Plan, exercise price, vest 100% on the date of the grant

4 terms

Stock Options financial

"The stock options, granted on March 31, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

2021 Equity Incentive Plan financial

"granted on March 31, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan"

exercise price financial

"conversion or exercise price of $1.4000 for the underlying common stock"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest 100% on the date of the grant financial

"representing the right to buy shares of common stock, vest 100% on the date of the grant"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Guerrero Ramiro

(Last) (First) (Middle)

444 WEST LAKE STREET, SUITE 1700

(Street)

CHICAGO ILLINOIS 60606

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MAIA Biotechnology, Inc. [ MAIA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$1.4	03/31/2026		A		27,258		03/31/2026(1)	03/31/2036	Common Stock	27,258	$0	27,258	D

Explanation of Responses:

1. The stock options, granted on March 31, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

	/s/ Ramiro Guerrero	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did MAIA (MAIA) director Ramiro Guerrero report in this Form 4 filing?

Director Ramiro Guerrero reported receiving a grant of 27,258 stock options. These derivative securities give him the right to buy MAIA common stock, providing equity-based compensation aligned with shareholder interests under the company’s 2021 Equity Incentive Plan.

How many MAIA (MAIA) stock options were granted to Ramiro Guerrero and at what price?

Ramiro Guerrero was granted 27,258 stock options with an exercise price of $1.40 per share. Each option allows the purchase of one share of MAIA common stock, giving him a leveraged way to participate in the company’s future share performance.

When do Ramiro Guerrero’s MAIA (MAIA) stock options vest and become exercisable?

The stock options granted to Ramiro Guerrero vest 100% on March 31, 2026 and are exercisable beginning that same date. Immediate vesting means he has full rights to exercise all options as soon as they are granted, subject to the option terms.

When do the MAIA (MAIA) stock options granted to Ramiro Guerrero expire?

The options granted to Ramiro Guerrero expire on March 31, 2036. This provides a ten-year exercise window from the March 31, 2026 grant date, allowing significant time for potential exercise depending on MAIA’s stock performance and his personal decisions.

Under which plan were Ramiro Guerrero’s MAIA (MAIA) stock options granted?

The options were granted under MAIA Biotechnology, Inc.’s 2021 Equity Incentive Plan. Such plans are commonly used to provide long-term, stock-based compensation to directors and employees to help align their interests with those of shareholders over time.